Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Positive

AI Analysis

Summary

Tyra Biosciences announced pricing of a $400 million underwritten offering of common stock and pre-funded warrants to fund its clinical-stage precision medicine development programs focused on FGFR biology.

Importance:6/10

Sentiment:

0.30

equity offeringcommon stockpre-funded warrantscapital raiseFGFR

Related Companies

$TYRA

Read the original article

Published by PR Newswire Biotech on September 14, 2026 10:45 AM

Read Original